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Cardiac remodeling describes the heart’s multimodal response to a myriad of external or
intrinsic stimuli and stressors most of which are probably only incompletely elucidated
to date. Over many years the signaling molecules involved in these remodeling
processes have been dichotomized according to a classic antagonistic view of black
and white, i.e., attributed either a solely maladaptive or entirely beneficial character. By
dissecting controversies, recent developments and shifts in perspective surrounding the
three major cardiac signaling molecules calcineurin (Cn), protein kinase A (PKA) and
calcium/calmodulin-dependent kinase II (CaMKII), this review challenges this dualistic
view and advocates the nature and dignity of each of these key mediators of cardiac
remodeling as a multilayered, highly context-sensitive and sophisticated continuum that
can be markedly swayed and influenced by a multitude of environmental factors and
crosstalk mechanisms. Furthermore this review delineates the importance and essential
contributions of degradation and proteolysis to cardiac plasticity and homeostasis and
finally aims to integrate the various aspects of protein synthesis and turnover into a
comprehensive picture.
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Introduction
Heart failure is the leading cause of death in industrialized countries (Nichols et al., 2014).
It is generally preceded by remodeling processes to adapt to alterations in wall tension in
the myocardium or stress by external (hormonal) stimuli. In this regard, cardiac remodeling
describes the heart’s fascinating capability to respond and adapt to various stimuli. The
mechanisms of cardiac plasticity, i.e., the potential of the heart to shrink or grow, are tremendous
as the dynamic growth range of the myocardium exceeds 100% (Hill and Olson, 2008).
Successful adaption to and adequate reduction of increased wall tension are ultimate goals
of cardiac remodeling and facilitating preservation or even augmentation of cardiac pump
Abbreviations: AKT, Protein kinase B (PKB); ANF, atrial natriuretic factor; βAR, beta-adrenergic receptor; BNP,
brain natriuretic peptide; CaMKII, Calcium/Calmodulin-dependent Kinase II; CnA, Calcineurin A; CnB, Calcineurin
B; Cn, Calcineurin; cAMP, Cyclic adenosine monophosphate; DCM, Dilated Cardiomyopathy; DRM, Desmin-Related
Cardiomyopathy; ERK, extracellular-signal-regulated kinases; Fbxl22, F-box and leucine-rich repeat protein 22; HCM,
Hypertrophic Cardiomyopathy; HDAC, Histone Deacytelase; MEF-2, myocyte enhancer factor-2; MFM, Myofribrillar
Myopathy; MuRF,Muscle Ring Finger Protein; NFAT, nuclear factor of activated T cells; PKA, Protein Kinase A; PKC, Protein
Kinase C; RCAN, regulator of calcineurin; ROS, Reactive Oxygen Species; UPS, Ubiquitin Proteasome System.
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function (Frey and Olson, 2003; Hill and Olson, 2008).
The multifaceted mechanisms of cardiac remodeling and
plasticity have traditionally been divided into beneficial (or
“physiological”) or maladaptive (or “pathological”) hypertrophic
remodeling of the heart on the one hand and cardiac atrophy on
the other hand.
While cardiac growth during maturation (“postnatal
hypertrophy”), maternal cardiac growth during pregnancy
and exercise-induced cardiac hypertrophy are all considered
physiological entities of hypertrophy, pathological hypertrophic
responses are observed upon sustained neurohumoral activation
and abnormal mechanical stretch of the myocardium as common
findings of various cardiac disease entities. These include but
are not limited to ischemic events (myocardial infarction),
pressure overload conditions such as arterial hypertension and
aortic valve stenosis, genetic disorders due to alterations in key
sarcomeric or metabolic proteins as well as infectious and toxic
triggers (Hill and Olson, 2008; Kehat and Molkentin, 2010;
van Berlo et al., 2013; Tham et al., 2015). Atrophic remodeling
is generally observed in patients with protracted bed rest and
ventricular unloading as well as malignant disease (Hill and
Olson, 2008; Cosper and Leinwand, 2011; Springer et al.,
2014).
Physiological hypertrophy of the heart—as it is observed
in postnatal growth as well as in response to pregnancy and
exercise—is characterized by a fine-tuned and orchestrated
process of beneficial adaptations. These modulations result
in decreased cardiac wall stress, augmentation of pumping
performance and improvements of vascularization, while
maladaptive effects of the increased workload that lead to
hypertrophic remodeling are countered and kept at bay. Various
signaling molecules and pathways have been shown to take
part in these adaptive processes and several excellent reviews
have summarized our present knowledge on this physiological
aspect of cardiac remodeling (Hill and Olson, 2008; Maillet et al.,
2013). Generally considered as beneficial, these pathways are
triggered by endocrine mediators or mechanosensors governing
a number of adaptive intracellular signaling cascades. Ligands
that result in physiological downstream signaling include
vascular endothelial growth factor B (VEGF-B), insulin, growth
hormone (GH) and insulin-like growth factor (IGF1) as well
as the thyroid hormone triiodothyronine (T3) (Yoshida et al.,
2010; Maillet et al., 2013; Tham et al., 2015). Via their respective
receptors, these stimuli converge on downstream pathways
controlling the induction of adaptive gene programs and protein
synthesis, and direct cellular metabolism and energy production.
Well-characterized cascades and pathways regulating these
homeostatic mechanisms comprise phosphoinositide 3 kinase
(PI3K)/AKT, mTOR complex 1 (mTORC1), ERK1/2 and
AMP-activated protein kinase (AMPK) (Baker et al., 1993; Liu
et al., 1993; McMullen et al., 2003; Seth et al., 2009; Bostrom
et al., 2010; Zhang et al., 2010). Translating stretch-stimuli
to downstream signaling, the mechanosensing apparatus is
controlled by transient receptor potential (TRP) channels,
integrins and various z-disc associated proteins such as muscle
LIM protein (MLP), actinin-associated LIM protein (ALP) and
Nebulette (NEB) as well as the sarcomere-spanning protein titin
(Linke, 2008; Seth et al., 2009; Frank and Frey, 2011; Luedde
et al., 2011; Hamdani et al., 2013; Maillet et al., 2013). While
the notion of (these) mediators as the “good guys” in cardiac
remodeling seems very appealing and is founded on robust
scientific work(s), a note of caution seems advisable not to fall
for a false dichotomy bearing in mind what Paracelsus postulated
about 500 years ago: “Dosis sola venenum facit” (Shiojima et al.,
2005; Hill and Olson, 2008; Tham et al., 2015).
Pathological hypertrophic remodeling on the other hand—
while initially compensatory by reduction of ventricular wall
stress and temporal preservation of cardiac pump function—
eventually evolves into a devastating spiral of maladaptive
alterations culminating in heart failure and death (Hill and
Olson, 2008; Kehat and Molkentin, 2010; Burchfield et al., 2013;
Molkentin, 2013; Tham et al., 2015). In this regard, pathological
hypertrophic remodeling is characterized by multiple facets of
ultimately maladaptive mechanisms such as altered calcium
handling, changes in metabolic patterns and gene expression,
affection of individual cell fate and survival as well as
modifications of the extracellular environment by fibrosis.
Cardiac stress by increased neurohumoral activation (mainly
endothelin 1, angiotensin II and catecholamines) and abnormal
mechanical stretch converge on a number of sensors (mostly G-
proteins and strain-sensitive cellular elements) which translate
these stimuli into respective stress response pathways (Hill
and Olson, 2008; Kehat and Molkentin, 2010; Burchfield
et al., 2013; Molkentin, 2013; Tham et al., 2015). Key second
messengers that were suggested in this regard include calcium,
phospholipase C, guanylyl, and adenylyl cyclases. Downstream
kinases, phosphatases and other enzymes with critical roles
in pathologic remodeling comprise calcineurin, protein kinase
A (PKA) and C (PKC), cGMP-dependent protein kinases
(PKG) calcium-calmodulin-dependent kinase II (CaMKII) and
mitogen-activated protein kinases (MAPKs) with their respective
downstream components—to name but a few (Benovic et al.,
1986; Molkentin et al., 1998; Allen and Leinwand, 2002; Backs
et al., 2006, 2009; Casey et al., 2010; Kehat and Molkentin, 2010;
Burchfield et al., 2013; van Berlo et al., 2013; Kreusser et al., 2014;
Tham et al., 2015).
Several outstanding reviews have been written in recent
years dissecting details of these mediators and pathways integral
to maladaptive/pathological remodeling processes (Kehat and
Molkentin, 2010; Burchfield et al., 2013; van Berlo et al., 2013;
Bisping et al., 2014; Tham et al., 2015). Therefore this review will
focus on a very limited number of crucial effectors highlighting
new aspects and shifts in perspective that might challenge long-
standing dogmas.
Notably, RNA-based signaling pathways andmediators as well
as epigenetic and other posttranslational modifiers are currently
evolving as further crucial contributors to cardiac remodeling.
However, elaborations on these developments would transcend
the scope of this review. Furthermore they have extensively been
covered in recent publications and reviews that focused on each
of the above issues individually (Papait et al., 2013; Lehmann
et al., 2014; Liu et al., 2015; Gillette andHill, 2015; Philippen et al.,
2015; Piccoli et al., 2015; Thum and Condorelli, 2015; Uchida and
Dimmeler, 2015).
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Allegory: Cardiac Remodeling as Tuning of
a Machine
Allegorically, cardiac plasticity could be referred to as the
maintenance and adjustment of a machine subjected to heavy
and undulating workload. The machine (heart) can be optimized
(remodeled) by technicians (key mediators) to perform according
to the present demand by employing different fuel (metabolic),
spare parts and logistics (structural and functional alterations).
These remodeling efforts can either be construed as long-
lasting, sustainable and deliberate optimizations (as it is generally
observed in physiological hypertrophy), or endeavors can be
targeted at drastic, short-term improvements which will not be
sustainable for a longer period of time but provide immediate
and powerful responses to increased demands (as observed
in many aspects of pathological hypertrophy). Furthermore, it
appears crucial whether the demand will have to be fulfilled
infinitely (analogous to many pathological stress models) or
whether periods exist when the machine can (temporarily)
cool down and reduce its output (as in exercise-related
hypertrophy).
Atrophy on the other hand could be seen as dismantling of a
machine and its appendices in response to reduced demand. This
dismantling process can be achieved by a multitude of different
ways depending on focus and technique of involved technicians
and parties.
Finalizing this allegorical approach, the technicians (key
mediators and signaling molecules) driving these changes of
the machine may be similar or even the same in various
aspects of remodeling. However, their intentions, perspectives
and approaches may be different depending on a vast number of
environmental, extrinsic and intrinsic factors.
Translating this simile to cardiac pathophysiology, it is
our opinion that key protagonists in cardiac plasticity may
not as easily be characterized as “good” or “bad,” beneficial
or maladaptive. To our minds, these essential mediators may
exert different functions and adaptations depending on timing,
duration and dosage of respective stimuli as well as crosstalk
with other crucial protagonists that are simultaneously activated
leading to numerous distinct posttranslational modifications.
For instance, the phosphatase calcineurin and its role in
cardiac remodeling have been studied for almost two decades
now (Molkentin et al., 1998; Molkentin, 2013). While it was
initially described and for a long time considered only as key
mediator of pathological hypertrophy and remodeling, evidence
has been accumulating in recent years that calcineurin might
also play an important role in physiological cardiac growth
(Heineke et al., 2010a; Felkin et al., 2011; Chung et al., 2013;
Hudson and Price, 2013; Molkentin, 2013; Kreusser et al.,
2014; Mattiazzi and Kranias, 2014). The resulting scientific
discussion whether calcineurin is the “bad guy” in cardiac growth
nicely illustrates how complex cardiac remodeling actually is: it
raises the question, whether the sophisticated means of cardiac
hypertrophy and remodeling can simply be broken down into
bad or good, black or white, or whether we should not consider
the multifaceted and finely tuned cardiac response mechanisms
as a continuum (of shades of gray) (Figure 1).
FIGURE 1 | Illustration of good and evil as an optical illusion/ambigram.
This illustration of the words good and evil in the context of an optical illusion is
implemented to emphasize two things: 1. Expectations drive our perception
and may therefore create a bias, i.e., if we are looking for something positive,
we will probably recognize the word good first. If negative expectations prevail,
the word evil will most likely be seen first. In this regard, we would like to
emphasize that research efforts are prone to hold to the same pattern and this
bias has to be mindfully dealt with and kept in mind. 2. The idiomatic phrase of
“two sides to every coin” is reflected in the concomitant depiction of good and
evil serving as a simile that key mediators of cardiac remodeling processes
cannot be dichotomized in solely good or bad protagonists as the nature and
dignity of their signaling will range a context-sensitive continuum with positive
(good) and negative (evil) results. Good-Evil Ambigram designed by and
courtesy of Punya Mishra (punyamishra.com).
To our minds, future research should therefore concentrate
on elucidating the myriad of crosstalk mechanisms between the
currently identified main pathways and key protagonists. This
will enable us to meticulously modulate the major signaling
pathways and molecules by augmenting those sidetracks that are
desirable in response to a given stressor, while repressing those
that perturb or prohibit adequate cardiac homeostasis.
While there is broad consensus on the fact that hypertrophy
and atrophy can be either beneficial or maladaptive, the exact
triggers, mediators and pathways leading to these distinct entities
are under constant debate. In this regard, several mediators that
had been classified as maladaptive have been rehabilitated over
the years, whereas seemingly benign players have been attributed
potential “dark sides” (Heineke et al., 2010a; Peng et al., 2010;
Felkin et al., 2011; Chung et al., 2013; Zhang et al., 2013; Kreusser
et al., 2014; Li et al., 2014; Mattiazzi and Kranias, 2014; Tham
et al., 2015).
As cardiac remodeling mechanisms involve a myriad of
different protagonists and interactions, this review will focus on
ongoing controversies and current developments surrounding
adaptive vs. maladaptive signaling in cardiac remodeling
(Calcineurin, PKA, CaMKII) as well as shifts in perspective in
terms of relative importance of select mechanisms in cardiac
remodeling (namely proteasomal/degradation mechanisms).
Calcineurin-Signaling
Calcineurin (Cn), one of the heart’s most intensively studied
enzymes, is a calcium-dependent serine/threonine phosphatase
controlling key functions and processes in response to a wide
range of stress stimuli. Calcineurin is composed as a heterodimer
of catalytic (CnA) and smaller regulatory subunits (CnB) with
CnA-alpha and CnA-beta as well as CnB1 constituting the
relevant myocardial isoforms (Taigen et al., 2000; Bueno et al.,
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2002). Generally activated by calcium (or to a lesser extent
calpain-cleavage), calcineurin dephosphorylates nuclear factor
of activated T cells (NFAT) as its major downstream target
(Molkentin et al., 1998; Hogan et al., 2003; Wilkins et al.,
2004). Upon dephosphorylation, NFAT in turn translocates to
the nucleus where it orchestrates the re-activation of fetal genes
such as atrial natriuretic factor (ANF), brain natriuretic peptide
(BNP) and skeletal actin (SA) as part of the prototypical cardiac
stress response (Molkentin et al., 1998; Hogan et al., 2003; Frey
et al., 2004; Wilkins et al., 2004; Frank et al., 2007). While it is
important to note that this activation of the fetal gene program
principally constitutes adaptive efforts to cope with the increased
cardiac stress, it is still generally perceived as an epiphenomenon
and utilized as a marker of unresolved and (therefore in the long
run) pathological stress.
Almost two decades ago, Molkentin and Olson—in a very
elegant study—first described calcineurin as a key mediator
of pathologic cardiac hypertrophy and consecutive progression
to heart failure (Molkentin et al., 1998). In the following,
numerous studies elaborated on the role of calcineurin in cardiac
hypertrophy and remodeling as well as heart failure. These
well conducted studies provided overwhelming evidence that
calcineurin is indeed at the center of cardiac hypertrophy and
remodeling (Zou et al., 2001; Hill et al., 2002; Wilkins et al.,
2004; Molkentin, 2013; van Berlo et al., 2013). In this regard,
loss of function models by either targeting calcineurin directly
(Zou et al., 2001; Bueno et al., 2002) or one of its modulators
such as regulator of calcineurin (RCAN), AKAP-79 or Cabin-1
(De Windt et al., 2001; Rothermel et al., 2001; Hill et al., 2002)
established beyond doubt that downregulation of calcineurin
prevented cardiac hypertrophy.
Moreover, data from most experiments on pharmacological
inhibition of calcineurin fortified this notion (Sussman et al.,
1998; Burchfield et al., 2013; Molkentin, 2013). Consequently,
overexpression studies with either activated calcineurin
(Molkentin et al., 1998) or knockdown of its negative modulators
(Frey et al., 2004) provided the complimentary picture of
increased susceptibility to heart failure in the wake of exaggerated
(pathological) hypertrophy (Molkentin, 2013).
Therefore, the vast majority of experiments led to the general
opinion that calcineurin is the “bad guy” in cardiac remodeling,
following the classical black-and-white dualism of attributing
either solely “pathological” or “physiological” qualities and
functions to a given cellular component or signaling pathway.
In recent years, this (false) dichotomy has evolved into a
more sophisticated view of calcineurin in particular and cardiac
remodeling in general (Heineke et al., 2010a; Felkin et al., 2011;
Heineke and Ritter, 2012; Chung et al., 2013; Molkentin, 2013;
Seto et al., 2013; Kreusser et al., 2014). In this regard, the entirely
black (-and-white) picture has evolved as several shades of gray
have been elucidated in calcineurin’s role.
Although robust scientific evidence demonstrates the
maladaptive nature of many pathways on which calcineurin
has a major impact, a number of studies on protective aspects
of calcineurin-mediated signaling have accumulated over the
past decade. Furthermore, one pitfall from studies on regulators
of calcineurin, that deserves mentioning, concerns the notion
that these regulators of calcineurin may not only or primarily
target calcineurin, but may very well also affect other important
signaling mediators.
While first evidence of protective aspects of calcineurin
signaling was already observed in terms of anti-apoptotic
properties by De Windt et al. (2000), a number of studies in
the years to follow fortified the notion that calcineurin may
indeed provide beneficial signaling under special circumstances
and should not be reduced to the maladaptive and destructive
culprit (Bueno et al., 2004; Frey et al., 2008; Heineke et al.,
2010a; Chung et al., 2013; Kreusser et al., 2014). These studies
rather served as a warning against demonizing calcineurin in
the wake of compelling data on maladaptive aspects of excessive
calcineurin activity.
Consistent with this notion of a context-sensitive dignity
of calcineurin signaling, a knock-out study of calsarcin-2, a
negative modifier of calcineurin activity in skeletal muscle, even
demonstrated enhanced exercise performance in absence of
a myopathic phenotype (Frey et al., 2008), while deletion of
calsarcin-1, the cardiac-enriched isoform repressing calcineurin
activity, resulted in accelerated cardiomyopathy and heart failure
due to exaggerated calcineurin signaling (Frey et al., 2000, 2004,
2008). These exciting observations hinted at multiple layers of
calcineurin signaling with physiological facets.
Intriguingly, Leinwand and colleagues published data on the
importance of calcineurin in regard to cardiac hypertrophy
during pregnancy, another classical prototype of physiological
cardiac remodeling (Chung et al., 2013). In particular, they
show calcineurin to be upregulated in pregnant mice as part
of physiological cardiac remodeling during early pregnancy.
Their observation of biphasic regulation of calcineurin during
pregnancy supports the idea that timing and intensity of a
stimulus and its responsive signaling cascades might be more
important than the individual effectors themselves in terms of
long-term consequences of the respective stimuli (Chung et al.,
2013). Furthermore, their observations strengthen the notion
that no single mediator, but crosstalk between signaling cascades
(specifically calcineurin, ERK and Akt as well as hormonal
balances) constitutes the paramount principle governing cardiac
response mechanisms to the physiologic remodeling stimuli
induced by pregnancy. Therefore, context and duration of
calcineurin activation may be the key determinants whether
calcineurin exerts its predominantly negative effects on cardiac
remodeling pathways or whether it contributes to adaptive and
beneficial signaling cascades in response to stressors (Chung
et al., 2013).
Insight on regulation of the nature of calcineurin signaling has
also been provided by Kreußer et al., illustrating calcineurin as a
key contributor to various entities of hypertrophy, but CaMKII
as a major mediator in conducting maladaptive stimuli (Kreusser
et al., 2014). Indeed, calcineurin appears to be (co-)regulated by
CaMKII.While co-activation during pathological stress results in
significant impairment of cardiac function in the wake of cardiac
remodeling, deletion of the two cardiac CaMKII genes δ and γ
in this setting is sufficient to generate a cardiac phenotype that
resembles a more physiological nature (calcineurin-dependent
cardiac hypertrophy without significant systolic dysfunction).
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This observation provides evidence for the conclusion that
calcineurin—while contributing to hypertrophic remodeling—
may confer beneficial changes in a context-dependent response
to external stressors (Kreusser et al., 2014).
Observations from studies by Lara-Pezzi’s group add another
layer of complexity, as they show induction of a splicing
variant of calcineurin (CnAβ1) to be protective after myocardial
infarction (Felkin et al., 2011). These findings hint at intricate
and sophisticated switching mechanisms in response to cellular
stressors emphasizing that no single pathway, but the interactions
of multiple cascades may determine remodeling to be adaptive or
maladaptive.
In an interesting review, Heineke and Ritter elaborate on
the concept of compartment/subdomain-specific modification
of calcineurin activity. This would allow for context-dependent
physiological or pathological means of remodeling (Heineke
and Ritter, 2012). Work on the calcium and integrin-binding-
protein-1 (CIB1) exemplarily illustrate how differential binding
and translocation of important cellular signaling mediators (in
this case calcineurin) affect the nature of downstream effects and
course of remodeling by compartmentalization (Heineke et al.,
2010). It is still unclear to what degree this concept of “fishing for
calcium” by different mediators of stress signals can unravel the
mysteries of the diverse characters of cardiac remodeling.
Looking further downstream at possible modifiers of
calcineurin signaling that may sway the dignity of a stimulus,
interactions with other transcription factors (such as MEF2,
AP-1, GATA4) as effectors of multiple upstream cascades
modify NFAT-dependent DNA-interaction and integrate various
pathways into meticulously tuned stress responses (Hogan et al.,
2003; Heineke et al., 2010; Heineke and Ritter, 2012).
Taken together, it is well established that calcineurin is
at the center of cardiac hypertrophy. However, evidence is
accumulating that calcineurin’s role may very well be part
of a continuum of (fifty or more) shades of gray in cardiac
remodeling rather than confined to the black-and-white dualism
that dominated the last decades of research in the field of cardiac
remodeling.
Protein Kinase A—Signaling in Cardiac
Remodeling
Protein kinase A or cyclic AMP-dependent Kinase (PKA)
constitutes the canonical downstream effector of the β-
adrenergic cascade in myocardial signaling. Activation of
the beta-adrenergic receptor (βAR), perhaps the heart’s most
crucial subclass of G-protein coupled receptor (GPCR), by
catecholamines primarily elicits an increase in cellular cAMP
via induction of cytosolic adenylyl cyclase (Benovic et al.,
1986; Xie et al., 2013; van Berlo et al., 2013; Tham et al.,
2015). Consequently, a number of critical signaling chains
and downstream effectors are activated, contributing greatly
to the immediate cardiac stress response (“fight or flight”
concept) by boosting myocyte inotropy, chronotropy, and
lusitropy. Mechanistically, elevation of cAMP predominantly
results in activation of PKA. Activated PKA in turn rules over
numerous critical downstream pathways by phosphorylating
pivotal calcium-handling proteins and crucial parts of the
myocytes’ contractile apparatus targeted at optimization of
cardiac contractility and (augmented) function. In this regard,
PKA is at the heart of the myocytes’ signaling pathways
which integrate stimuli and stressors into orchestrated cascades
that enhance cardiac remodeling and therefore ensure short-
and long-term homeostasis and integrity of cellular functions
(Benovic et al., 1986; Backs et al., 2011; Burchfield et al.,
2013; Xie et al., 2013; van Berlo et al., 2013; Tham et al.,
2015). As tremendous efforts in PKA research have elucidated
and meticulously characterized a myriad of aspects of PKA
signaling, this review can only highlight some recent frontiers,
controversies and shifts in perspective. It aims to pick up on
the notion that—with increasing knowledge—simplified models
might have to make room for concepts of multi-layered and
meticulously tuned processes, since key players themselves and
associated cellular pathways prove even more complex than
initially perceived.
Therefore, this review will focus on the following aspects of
cardiac remodeling as far as PKA is concerned: importance of
duration and alternate means of PKA stimulation/activation, and
(in the following section) crosstalk of PKAwith CaMKII, perhaps
the most intricately intertwined protagonists and pathways of
myocyte remodeling.
The (erratic) viewpoint of PKA as a detrimental player in
cardiac remodeling and heart failure was significantly stimulated
by the adverse cardiac phenotype observed in a transgenic mouse
model overexpressing constitutively active PKA (Antos et al.,
2001). In the years to follow, a more sophisticated picture of
the role of PKA in the myocyte’s stress response and remodeling
processes emerged as the significance of dosage, time dependency
and hierarchic crosstalk with other mediators such as CaMKII
became apparent. In this regard, it became clear that PKA elicits
protective effects upon immediate β-adrenergic stimulation,
e.g., by phosphorylation of sarcomeric structures such as titin,
while transgression to heart failure was actually found to be
associated with decreased phosphorylation of PKA dependent
targets. These findings fortified the idea that PKA might have
a more pronounced role in early remodeling as opposed to
chronic stress (Yamasaki et al., 2002; Kruger and Linke, 2006;
Grimm and Brown, 2010; Backs et al., 2011; Fischer et al.,
2013a).
In line with these observations, short-term stimulation of the
β-adrenergic cascade confers a number of protective effects and
mediates essential “fight or flight” responses. Chronic stimuli
cause the remodeling processes to turn into a detrimental spiral
of beta-receptor desensitization and pathologic hypertrophy
with subsequent development of heart failure. Long-term β-
adrenergic stimulation leads to negative modulation of the
respective receptors as well as downstream effectors and targets
by a number of key regulators, but the exact mechanisms of
this duration-dependent switch in effects of beta-adrenergic
stimulation and stress are incompletely understood (Engelhardt
et al., 1999; Bristow, 2000; Hill and Olson, 2008; Zhang et al.,
2013; van Berlo et al., 2013). However, it is widely accepted
that GPCR receptor kinases (GRKs) constitute a pivotal class of
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enzymes which restrict the dynamic range of βAR-function by
phosphorylation of the receptors themselves and by modification
of beta-arrestin signaling, a side-track of the β-cascade which
is crucial for protective downstream effects (Strulovici et al.,
1984; Benovic et al., 1986). Targeting of these duration-
dependent negative regulators offers a promising approach to
take advantage of PKA-mediated increases in cardiac contractility
while repressing those intermediates andmodulators in the PKA-
cascade that lead to detrimental remodeling and subsequent heart
failure (van Berlo et al., 2013). For instance, blocking GRK2
interaction with the GPCR alleviates pathologic remodeling,
whereas amplified contractility is still observed (Casey et al.,
2010).
The second aspect of PKA that we would like to zero in on
in this review is the means by which PKA gets activated, as this
seems to play a critical role in downstream effects. Furthermore,
it illustrates that various environmental stimuli may divergently
modify the character and dignity of remodeling and therefore
induce distinctly different phenotypes, although they employ one
and the same kinase. The above depicted β-adrenergic cascade
serves as the predominant extracellular means to activate PKA.
However, a number of alternate mechanisms have been proposed
with reactive oxygen species (ROS) as the most intriguing elicitor
(Brennan et al., 2006; Sag et al., 2013; van Berlo et al., 2013;
Wagner et al., 2014; Tham et al., 2015).
Reactive oxygen species (ROS) and respective sensors and
counterparts are integral parts of (sub)cellular signaling in
many compartments of each cell. They contribute greatly to the
myocyte’s stress response and remodeling efforts (Burgoyne et al.,
2013; Sag et al., 2013; Wagner et al., 2014; Tham et al., 2015).
In this regard, ROS can either directly affect target structures by
oxidation or trigger a number of enzymes to modify downstream
effectors leading to altered calcium signaling and contractility,
gating of ion channels as well as differential regulation of
homeostatic mechanisms concerned with trophy, metabolism
and cell survival (Burgoyne et al., 2013; Sag et al., 2013; Wagner
et al., 2014; Tham et al., 2015).
Therefore, amongst others a publication from Phil Eaton’s
group deserves special attention. In multiple well-conducted
experiments they demonstrate dose-dependent activation of
PKA by dimerization of its regulatory subunit and consecutive
compartmentalized modification of respective PKA targets.
Notably, this activation of PKA by H2O2 was independent
of cAMP levels, the mediator of βAR-induced PKA activation
(Brennan et al., 2006). Interestingly, the study provides evidence
that the postulated targets of oxidant-induced PKA are at
least in part congruent with those phosphorylated upon
classic beta-adrenergic activation of PKA. While many of
the mechanistic details of this alternate pathway of PKA
activation remain elusive, it has become evident that oxidant-
induced activation confers a means of targeting PKA to its
subcellular compartments and inducing its kinase activity in
these select environments. Furthermore, these findings imply
that the effects of PKA may be dependent on and vary
with multiple environmental factors (β-adrenergic stimulation,
ROS, intracellular calcium, etc.) whose crosstalk and relative
contributions may determine PKA’s quintessential role in any
given situation. For instance, ROS-induced activation of PKA—
similarly to beta-adrenoreceptor-mediated induction of PKA—
results in an increase of cardiac contractility. However, the
degree, dosage and duration of ROS stress appear to strongly
influence these remodeling mechanisms as strong and long-
lasting ROS stimuli seem to reverse the aforementioned pro-
inotropic effects (Goldhaber and Liu, 1994; Yao et al., 2003).
Suggesting another regulatory principle compatible to the
previously described differential effects of different isoforms in
calcineurin signaling, Brennan and colleagues also speculate on
the possibility that redox-sensitivity applies mainly for type I
PKA, while the type II entity may be more prone to β-adrenergic
signaling (Brennan et al., 2006; Felkin et al., 2011).
Therefore this example of differential activation of PKA by
ROS (as well as the regulatory mechanisms in terms of stability
and degradation touched upon later in this review) may serve as
another illustration of the complexity of cardiomyocyte signaling
and remodeling mechanisms.
CaMKII-Signaling in Cardiac Remodeling
Calcium-Calmodulin-dependent Kinase II (CaMKII) is at the
center of multiple cardiac signaling cascades and modulates
the heart’s response to various extrinsic and intrinsic stimuli
(Anderson et al., 2011; van Berlo et al., 2013; Grandi et al., 2014;
Kreusser et al., 2014; Kreusser and Backs, 2014; Mattiazzi and
Kranias, 2014; Weinreuter et al., 2014; Tham et al., 2015). The
main cardiac isoforms of CaMKII, gamma and delta, have been
studied in depth in terms of their role in cardiac remodeling
processes. As several excellent reviews (Anderson et al., 2011;
Maier, 2012; Fischer et al., 2013b; Herren et al., 2013) and
a very comprehensive topic series on CaMKII (synopsis in
Grandi et al., 2014) have extensively covered the spectrum of
CaMKII in cardiac physiology and pathology only very recently,
the scope of this review will limit its attention to interactions
and crosstalk with the aforementioned protagonists of cardiac
signaling, calcineurin and PKA, as well as emerging twists and
desiderata of CaMKII research.
In regard to the latter, CaMKII activation requires calcium
and calmodulin to dissolve the autoinhibitory conformation
of CaMKII, thereby exposing both the regulatory and catalytic
domain of the molecule. In the wake of prolonged activation,
autophosphorylation at T287 occurs as a major posttranslational
mechanism to stabilize CaMKII in its activated form (Meyer
et al., 1992; Erickson, 2014). In recent years, a number of
studies have uncovered multiple alternate posttranslational
modifications of CaMKII (especially of the regulatory domain
and mainly activating in nature) offering a new conundrum
as to the contributions and interdependency of these various
regulatory mechanisms (Erickson, 2014). Select principles of this
divergent activation of CaMK include oxidation, glycosylation
and nitrosylation as well as interactions with intracellular
proteins (such as alpha-actinin or the NMDA receptor in the
brain) (Jalan-Sakrikar et al., 2012; Burgoyne et al., 2013; Erickson
et al., 2013; Sag et al., 2013; Coultrap and Bayer, 2014; Erickson,
2014).
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As with calcium, the previously mentioned activation of
CaMKII via ROS seems especially intriguing as it parallels the
induction of PKA by ROS. This parallelism construes another
enigma in terms of the hierarchical, spatial and temporal patterns
and regulatory mechanisms that determine which of the two
kinases is preferentially targeted and therefore supreme in
its effects at any given time. Furthermore, this ROS/oxidant-
dependent co-induction of CaMKII and PKA is especially
enthralling, as both kinases do not only share a great number of
binding partners and downstream effectors such as sarcomeric
proteins (e.g., cMyBPC, actinin), calcium handling proteins
(RyR, PLN) as well as various calcium and sodium channels (e.g.,
NaV1.5), but sometimes even phosphorylate a protein at the exact
same amino acid position (Faul et al., 2007; Anderson et al., 2011;
Herren et al., 2013; Sag et al., 2013; Dobrev and Wehrens, 2014;
Mattiazzi and Kranias, 2014; Wagner et al., 2014).
In some instances, this mystery of multiplicity, redundancy
or even competition of PKA and CaMKII has been partially
unraveled, as PKA was demonstrated to regulate histone
deacetylase 4 (HDAC4) by inducing proteolysis, thereby
selectively repressing myocyte enhancer factor-2 (MEF2) activity
and shutting out CaMKII signaling tracks (Backs et al., 2011).
Interestingly, this modulation of HDAC4 confers a switch toward
a more protective cascade by favoring SRF over MEF2 as
HDAC4-NT’s primary target structure. In this way it serves as
a gateway disrupting sidetracks that would cause the nature of
cardiac remodeling to take a maladaptive direction (Backs et al.,
2011).
A second example of progress in this area refers to the
relative importance of the key signaling mediators calcineurin
and CaMKII in regard to their roles in (maladaptive) cardiac
remodeling. As previously delineated both signaling pathways
(CaMKII and calcineurin) critically contribute to the pressure
overload-induced phenotype of adverse remodeling, but
knockout of both cardiac CaMKII genes demonstrates the
supremacy of CaMKII for the maladaptive nature of remodeling
in this setting, while calcineurin—when isolated from CaMKII
crosstalk and interdependency—also seems to trigger beneficial
processes in terms of a more physiological remodeling phenotype
(Kreusser et al., 2014).
However, passing the buck to CaMKII and thereby advocating
it as the black sheep in terms of cardiac remodeling does
not seem justified since experimental evidence points at more
intricate and multi-layered regulatory mechanisms. For instance,
the isoform or subtype dependent variances in downstream
signaling described for CaN and PKAhave also been proposed for
CaMKII and may significantly complicate and impede simplified
explanations following a dualistic projection (Peng et al., 2010;
Mishra et al., 2011; Gray and Heller Brown, 2014).
To further elaborate on the enigma of multiplicity,
redundancy or even competition, the multi-adaptor z-disc
protein myopodin has not only been shown to be phosphorylated
by both PKA and CaMKII (both resulting in nuclear import
of myopodin), but has been shown to be dephosphorylated by
calcineurin, the third pivotal mediator of cardiac remodeling
covered in this review (Faul et al., 2007; Linnemann et al.,
2010). Similar data in terms of unresolved redundancy and/or
multiplicity exists in regard to calcium or sodium handling
proteins such as the RyR or the NaV1.5 channel (Camors and
Valdivia, 2014; Dobrev and Wehrens, 2014; Grandi and Herren,
2014). While most of the biological implications and functions
of these tantalizing observations remain elusive so far, these
findings are nevertheless illustrative of the concept that key
players in cardiomyocyte signaling significantly intertwine
with their intermediates and downstream effectors so that
dichotomizing protagonists in dualistic cascades may not always
be as helpful as initially thought.
Deciphering crosstalk of CaMKII and PKA as two of themajor
signaling kinases in the heart has intrigued scientists for years
and led to elucidation of various intermediates which constitute
indirect signaling loops and pathways that integrate signals from
one of these cascades into the other and modulate the response
of one kinase depending on the other’s signaling.
Exemplarily, recent works from Mika and colleagues
demonstrate a feedback loop in which CaMKII phosphorylates
PDE4D, which in turn leads to downregulation of cytosolic
cAMP levels and consequent inactivation of PKA (Mika et al.,
2015). Interestingly, although both kinases show this variety of
identical interaction partners and targets, direct interaction and
modulation of one of the kinases by the other has never been
demonstrated to date.
In summary, there is broad consensus in the scientific
community that factors like duration, intensity and
environmental setting of extrinsic and intrinsic stimuli are most
crucial for the downstream mediation of cardiac remodeling.
In this regard, the realization of signaling pathways and single
effectors integrating into a myriad of complex interactions
and crosstalk-dependent downstream effects have led to the
belief that these mechanisms of fine-tuning are paramount for
our understanding of how the heart construes various stimuli,
incorporates and orchestrates these into signaling cascades and
alters gene expression to adapt to these stimuli. Modulation of
interactions and crosstalk between cellular effectors, downstream
targets in regard to gene expression as well as modification
of the perception of stressors may therefore hold promise
for future therapeutic approaches rather than aiming for the
intermediates in signaling themselves—in reminiscence of the
Greek philosopher Sophocles who postulated: “Do not kill the
messenger!”
Protein Maintenance and Turnover as
Critical Setscrews of Remodeling
Growing Tired (?)—Get a Shrink Before Burn-Out!
Asmentioned above cardiac plasticity covers a wide and dynamic
range, which allows for distinct and impressive adaptations
to altered hemodynamics and demands. Key determinants of
cardiac homeostasis in this regard include mechanisms which
govern the dynamics of protein synthesis and degradation,
thereby creating an adequate equilibrium suitable for any given
situation. Over the past decades, research has mainly focused
on protein synthesis with its respective appendices, adaptations,
modulations and control mechanisms in an effort to elucidate
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therapeutic potential of modifications of key mediators in these
signaling pathways. In recent years, accumulating experimental
evidence has led to a gradual shift in perspective (Hill and
Olson, 2008; Portbury et al., 2011; Willis et al., 2014). While
modes of protein synthesis and their modulation have remained
as critical pillars in cardiac remodeling research, interest in
mechanisms of degradation and atrophy has steadily grown (Hill
and Olson, 2008; Portbury et al., 2012; Lavandero et al., 2013,
2015; Willis and Patterson, 2013; Willis et al., 2014). This is based
on the notion that protein synthesis and degradation—while
seemingly at opposing poles of cellular regulatory mechanisms—
are in reality closely associated and hugely intertwined balancing
mechanisms that guarantee adequate cellular responses and
homeostasis (Willis and Patterson, 2013).
Therefore, the second part of our review will focus on this shift
in perspective and the essential contributions of degradation and
proteolysis to cardiac plasticity and homeostasis.
The cell is in dire need of tools which ensure adequate removal
of misfolded or no longer-needed proteins as well as mechanisms
that allow for well-controlled and regulated conversion and
remodeling of its structural and functional units in response to
intrinsic and extrinsic stimuli (Willis and Patterson, 2013). This
deserves special emphasis in regard to the heart, more specifically
cardiomyocytes, as these cells are terminally differentiated and
characterized by a very limited regenerative potential (Willis and
Patterson, 2013). Therefore, cardiomyocyte homeostasis, health
and survival rely heavily on maintenance of protein quality
control as well as critical balancing of synthesis, folding and
turnover of proteins (Willis et al., 2009a). Cellular mechanisms
to achieve this equilibrium include molecular chaperones and
folding enzymes (nicely reviewed in Hartl et al., 2011; Christians
et al., 2014 and therefore only briefly touched upon here) and
coordinated systems for degradation and proteolysis, mainly
autophagy and the ubiquitin-proteasome system (UPS) (Willis
and Patterson, 2013; Willis et al., 2014; Lavandero et al.,
2015)—elaborated on below. Only briefly mentioned here, but
nevertheless very interestingly, SUMOylation has emerged as
another important factor in regard to modification of protein
turnover and homeostasis (Gupta et al., 2014).
Initially coined by Belgian biochemist Christian de Duve,
the term “autophagy” describes the basic cellular approach to
degrade and recycle dysfunctional or unnecessary components by
lysosomal digestion (Blobel, 2013; Ohsumi, 2014). In this process,
target structures are segregated into autophagosomes, double-
membrane vesicles, which are then amalgamated to lysosomes.
Consequently, lysosomal hydrolases mediate the breakdown
and recycling of target structures resulting in cellular clearance
(Lavandero et al., 2013, 2015; Ohsumi, 2014).
The Ubiquitin-Proteasome System is the second main effector
of cellular degradation (Willis and Patterson, 2013; Willis et al.,
2014; Drews and Taegtmeyer, 2014). While autophagy generally
tackles (larger) aggregates, fractions or whole organelles, the
UPS functions as a highly specific and meticulously tuned
machinery by targeting single molecules that need to be degraded
(Willis et al., 2014). Upon canonical labeling of lysine residues
with ubiquitin chains, dispensable proteins are recognized and
subsequently degraded by the 26S proteasome, a ubiquitous
protease, marking the catalytic destination of the UPS pathway.
Substrate-specificity of UPS-mediated degradation is achieved by
amyriad of different ubiquitin ligases, which exhibit idiosyncratic
binding sites tailored to their individual targets. Interestingly,
downregulation of CSN (COP9 signalosome) confers a general
reduction of F-box proteins, an important group of ubiquitin
ligases, resulting in cardiac hypertrophy and severe heart failure
(Su et al., 2011). This observation nicely depicts the homeostatic
role of ubiquitin ligases in cardiac remodeling.
Adding another layer of complexity, various deubiquitinating
enzymes may modify or even counteract the action of E3
ubiquitin ligases (Bosch-Comas et al., 2006; Bernardi et al., 2013).
There is significant crosstalk, cooperation and
interdependency between the two basic mechanisms of cardiac
proteolysis. In this regard, overload of and impairments in the
UPS lead to compensatory upregulation of autophagy as an
emergency solution or bypass to cope with the overflow. Yet, if
both major systems are overwhelmed and failing (hypertrophic)
remodeling accelerates and cardiac function declines (Tannous
et al., 2008a,b; Su et al., 2011; Willis and Patterson, 2013).
Substrate-specific recognition by E3-ligases and subsequent
degradation not only allow for the disposal of misfolded,
damaged or no longer necessary proteins but offer a finely tuned
and orchestrated means to direct cellular signaling. The cardiac
sarcomere deserves special emphasis in this regard, as it serves
as a pivotal node of signaling integrating stretch-responsive
messages originating from the cell membrane, calcium-derived
mechanisms of excitation-contraction (EC) coupling as well as
multiple other cellular pathways which modulate the heart’s
quintessential function: force-generation for contraction of blood
to supply the body with oxygen (Frank and Frey, 2011; Knoll
et al., 2011; Portbury et al., 2011; van Berlo et al., 2013).
Illustrating this notion, most of the cardiac ubiquitin ligases
identified to date target key sarcomeric proteins or molecules
entangled with its associated network of signal effectors. For
instance, the muscle-specific E3-ubiquitin ligase atrogin has
been shown to ubiquitinate and thus to facilitate degradation
of calcineurin (Li et al., 2004) which—as detailed above—
represents one of the crucial enzymes in mediation of cardiac
remodeling. Moreover, atrogin may exert its signaling effects
in regard to hypertrophic remodeling by inducing the FoxO-
transcription factor through non-canonical K63-ubiquitination
(Li et al., 2007). FoxO in turn may induce atrogin (Sandri et al.,
2004), while evidence suggests that at least in skeletal muscle
both of the aforementioned (FoxO and atrogin) are additionally
regulated by HDACs (Potthoff et al., 2007; Moresi et al., 2010).
This may serve as a beautiful illustration of the complex crosstalk
and interdependency of the UPS and key signaling elements of
the cell.
Furthermore, the cardiac muscle-RING finger proteins
(MuRFs) target parts of the contractile apparatus such as
troponin I (MuRF-1) and myosin heavy chain (MuRF-1 and−3).
In congruence, MuRFs (especially MuRF-1) have been shown
as essential modulators of the hypertrophic remodeling process
(Willis et al., 2007, 2009a,b, 2014; Fielitz et al., 2007a,b; Portbury
et al., 2011; Willis and Patterson, 2013). Of note, the classic
pathological vs. physiological dichotomy observed in research on
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other key players of myocardial remodeling is not commonly
attributed in UPS research, where seemingly contradictive or
at least multi-layered data have created the picture of gradual
continua of context- and stimulus-specific rather than ligase-
specific reactions and pathways. This complex nature of UPS-
mediated reactions to cardiac stress is marvelously illustrated by
contrasting works from Willis and colleagues: on the one hand
transgenic overexpression of MuRF-1 mediates cardioprotective
effects in models of ischemia, on the other hand MuRF-
1 transgenic mice demonstrate progressive decline in cardiac
function as well as increased susceptibility to TAC-induced heart
failure (Willis et al., 2007, 2009b). Additionally, studies by Fielitz
et al. show a loss of MuRF-3 to be detrimental as this deficiency
renders the heart more prone to rupturing after myocardial
infarction (Fielitz et al., 2007b). Furthermore, thesemice deficient
ofMuRF-1 andMuRF-3 show increased susceptibility for adverse
hypertrophic remodeling along with findings of storage and
aggregate myopathies (Fielitz et al., 2007a). The high redundancy
of E3 ligases in regard to their respective targets as well as the
critical involvement of the UPS in terms of metabolism add even
more layers of complexity (Adams et al., 2008; Witt et al., 2008;
Willis et al., 2014). Intriguingly, further downstream proteasome
modification itself can also contribute to or even sway the nature
of cardiac remodeling processes (Drews et al., 2010).
A second example of the absence of a black-and-white dualism
can be derived from data on atrogin in settings of myocardial
remodeling:
While the observation that atrogin-transgenic mice are
protected from TAC-induced pathologic cardiac hypertrophy is
promising, it is remarkable that the very same mice are still
prone to TAC-mediated deterioration of cardiac function on the
other hand (Li et al., 2004; Portbury et al., 2012). Furthermore,
atrogin-knockout mice exhibit both protection from pathologic
hypertrophic remodeling and resistance to pressure-overload
induced cardiac dysfunction (Usui et al., 2011).
These observations offer a conundrum that clearly opposes the
classic partition into solely “good” or “bad” players that has been
used in regard to other mediators of cardiac remodeling in the
past.
Myofibrillar myopathies (MFM)/desmin-related myopathies
(DRM), generally clustered as a subgroup of the heterogeneous
group of dilated cardiomyopathies (DCM), also highlight the
critical implications of the UPS for remodeling research. They
prove beyond doubt that loss of degradation capacities—
which is generally due to mutations in sarcomeric proteins,
that render these mutated proteins less stable in the constant
wear and tear, or even cause them to be misfolded from the
beginning—is indeed causative and crucial for the development
of hypertrophic remodeling and deterioration of cardiac function
in its wake (Kley et al., 2013; Willis et al., 2014; Willis and
Patterson, 2013; Schlossarek et al., 2014a). Desminopathy and
filaminopathy are the best described representatives of these
MFMs/DCMs. For the group of desminopathies, mutations in
either desmin or its molecular chaperone (CryAB) have been
shown to be associated with impaired autosomal degradation
of the respective aggregates. Identification of mechanisms to
enhance UPS- and autophagy-mediated elimination of these
devastating aggregates of misfolded proteins appears paramount
to counter adverse remodeling and consequent heart failure
(Willis and Patterson, 2013; Willis et al., 2014; Schlossarek et al.,
2014a). An exploratory study by Cohen and colleagues who
analyzed filament composition and breakdown in atrophying
muscle upon fasting suggests involvement of Trim32 in desmin
ubiquitylation and degradation (Cohen et al., 2012). It nicely
illustrates the need for further comprehensive in vivo studies
to delineate the roles of Trim32 and other ubiquitin ligases as
suitable catalysts for degradation of WT and mutant desmin and
its appendices as the prototypical proteins of DCM/DRM.
Filaminopathies deriving from mutated filamin entities may
also be promising objectives in UPS research, as two cardiac
ubiquitin ligases, MuRF-3 and fbxl22, have so far been identified
to target filamin C for proteasomal degradation and upregulation
of these E3 ligases may therefore offer great therapeutic potential
in this disease (Fielitz et al., 2007b; Spaich et al., 2012; Kley et al.,
2013; Willis et al., 2014).
Much the same applies for other types of cardiomyopathies
that derive from mutated sarcomeric proteins. For instance,
numerous studies demonstrate that mutations in cardiac
myosin binding protein C (cMyBPC) lead to hypertrophic
cardiomyopathy (HCM) associated with impairment of the
UPS, establishing cMyBPC as the paradigm of HCM-studies
(Schlossarek et al., 2014a,b). Conversely and illustrative of
the complexity of achieving homeostasis in regard to protein
turnover and maintenance, proteasomal inhibition appears to
ameliorate the decline in cardiac function in a hypertrophic
cardiomyopathy model of mutated cMyBPC (Schlossarek et al.,
2014b).WhileMuRF-1 has been shown to reduce cMyBPC levels,
this occurs independent of its ubiquitin ligase activity and is
likely due to indirect effects (Mearini et al., 2010). Furthermore,
promising observations from in vitro studies demonstrate atrogin
to be involved in degradation of mutated cMyBPC. On the
downside, atrogin fails to targetWT cMyBPC—potentially due to
divergent localization of mutant cMyBPC (Mearini et al., 2010).
These findings underscore that the underlying mechanisms
and their therapeutic potential remain largely elusive and
should be targeted by future research, along with intensive
efforts to identify further E3 ligases involved in cMyBPC
degradation.
The vast field of cardiomyopathies has seen significant
advances in identification of causative gene mutations along with
respective phenotyping. However, in many cases the implications
of these mutations in regard to the UPS have not been
understood yet and are far from utilization of the therapeutic
potential which a distinct mapping of culprits and mutated
target genes to respective ubiquitin ligases would harbor (Willis
et al., 2014; Drews and Taegtmeyer, 2014; Schlossarek et al.,
2014a). For instance, alpha-actinin, a key sarcomeric protein in
terms of structure and signaling, has repeatedly been implicated
in cardiac remodeling and disease development (DCM) but
so far only in vitro data exists on its mode of degradation
(Spaich et al., 2012). While the observation that the cardiac
E3 ligase fbxl22 facilitates the degradation of alpha-actinin is
auspicious, it plainly exemplifies and advocates, yet again, the
need for future remodeling research to shift in perspective
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from solely analyzing the side of protein synthesis to minutely
identifying and characterizing how each and every cardiac
protein is regulated in terms of its homeostatic equilibrium
and turnover.
Taken together this exemplary but to no end comprehensive
presentation of autophagy- and UPS-related cardiac disease
entities and mechanisms is supposed to reflect the multifaceted
involvement and key roles of the degradation machinery in
cardiac remodeling and disease development.
Conclusion and Future Perspective
Finally, to integrate both parts of our review we will provide
two examples that nicely illustrate and thus emphasize the
intertwining character of cardiac remodeling with its complexity
and diverse crosstalk mechanisms:
The first part of our review detailed evolving controversies on
major cardiac signaling pathways and their key protagonists—
namely calcineurin, PKA and CaMKII—while the second part
FIGURE 2 | Integrative illustration of the complexity and
context-sensitivity of cardiac remodeling. (A) Neutral illustration how
various setscrews determine the result of cardiac remodeling processes.
Multiple pivotal molecules such as calcineurin, PKA and CaMKII have been
identified as key mediators of myocardial signaling (green) in the remodeling
process (red). A dualistic perspective of “bad” and “good” mediators fails to
integrate the myriad of context-dependent stimuli and crosstalk mechanisms
(depicted as the blue setscrews in this illustration). Furthermore, protein
maintenance and degradation (purple) contribute to the dignity and nature of
cardiac remodeling processes. (B) Exemplary illustration of calcineurin’s role
in adaptive cardiac remodeling processes that result in a beneficial
phenotype. While a number of stimuli and setscrews remain only
incompletely understood or even elusive so far (purple), multiple relevant
extrinsic and intrinsic factors potentially modulate calcineurin signaling
toward a more beneficial response (depicted in light gray).
Pregnancy-associated cardiac remodeling has been shown to be beneficial
in nature; hormonal and temporal factors depicted here appear to contribute
significantly to this adaptive dignity of calcineurin signaling. (C) Contrasting
illustration of calcineurin’s role in a maladaptive setting promoting cardiac
remodeling processes that result in an adverse phenotype. While multiple
factors—especially in regard to protein turnover—remain only incompletely
understood or even elusive so far (purple), numerous extrinsic and intrinsic
stimuli and stressors drive calcineurin signaling toward pathological effects
with an adverse cardiac phenotype (depicted in dark gray). The pressure
overload phenotype has been intensively studied; evidence suggests that
calcineurin’s signaling is swayed toward a maladaptive course not only by
sudden onset, pronounced duration and intensity of the remodeling stimulus
but also by cofactors such as activated CaMKII.
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focused on the idea that not only protein synthesis but also
protein turnover and degradation are paramount for cellular
homeostasis. Despite huge efforts in both fields of research to
enhance our understanding how cardiac remodeling processes
are governed, it seems surprising that at least for two of the
formerly mentioned pivotal mediators of cardiac remodeling,
PKA and CaMKII, knowledge in regard to the regulation of their
turnover and degradation remains very scarce. To the best of our
minds, no ubiquitin ligase has yet been identified and proven as
a critical regulator of CaMKII. In terms of PKA ubiquitylation
and degradation, only the ubiquitin ligase Praja2 has so far
been shown to associate with and ubiquitinate the regulatory
subunit of PKA in specific compartments (Lignitto et al., 2011).
Furthermore, with atrogin and MuRF-1 only two ubiquitin
ligases have been validated to perform E3 ligase activity upon
calcineurin thereby targeting it for proteasomal degradation (Li
et al., 2004; Maejima et al., 2014; Schlossarek et al., 2014a).
In light of the multiplicity and redundancy seen for other key
cellular proteins (p53 is targeted by at least 10 different ubiquitin
ligases, proteasomal degradation of c-Jun has been shown to
be conferred by at least 4 different E3 ligases), it appears very
likely that a number of ubiquitin ligases targeting PKA, CaMKII
and CnA are still unidentified and may be very important for a
comprehensive picture of the mechanisms that control cardiac
remodeling (Portbury et al., 2012; Willis et al., 2014; Maejima
et al., 2014).
The second interesting notion highlighting the integrative
and highly complex mechanisms that govern cardiac plasticity
and remodeling concerns the observation that exercise,
therefore physiologic hypertrophic stimuli, may alleviate
myofibrillar myopathies and proteotoxicity in the wake of
UPS impairments and dysfunction (pathological cardiac
remodeling) or lead to improvement of UPS function itself
(Maloyan et al., 2007; Willis and Patterson, 2013; de Andrade
et al., 2015). This intriguing interdependency demands for
further clarification of the underlying crosstalk to enhance our
understanding how induction of certain mediators by exercise
may provide tools for renewal of cellular homeostasis in failing
myocardium.
In any case, this observation underscores the concept
that seemingly distant stimuli and protagonists of myocardial
signaling (exercise on the one hand, the UPS on the other hand)
intricately affect each other and prove the cardiac remodeling
processes to be comprehensive andminutely tuned programs that
integrate all cellular pathways into a highly plastic and flexible
machinery (Figure 2).
In summary, this review provides some thought-provoking
impulses on emerging or ongoing controversies and shifts in
perspective surrounding myocardial remodeling rather than
trying to comprehensively cover the myriad of elaborate
mechanisms of cardiac signaling.
Therefore the two key messages are:
1. Protagonists of cardiac remodeling demonstrate multifaceted
crosstalk and significant interdependency in a highly context-
sensitive nature. Therefore it is our opinion that they cannot
be easily classified in terms of a black and white dualism but
appear to roam a gradual continuum of “fifty (or more) shades
of gray.”
2. While protein synthesis and its regulation remain paramount
for our understanding of cardiac adaptations, a shift in
perspective has occurred in recent years as the mechanisms of
maintenance and turnover of proteins have increasingly been
recognized as essential aspects of sustained homeostasis—or
to put it in other words: “Growing tired (?)—get a shrink
before burn-out!”
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